Data Sheet 1_Efficacy and safety of transarterial chemoembolization plus donafenib with or

A single-center retrospective study of 278 patients with unresectable hepatocellular carcinoma treated between 2021 and 2024. The dataset compares tumor response, survival outcomes, and adverse events between two treatment regimens after propensity score matching. It was authored by Qi Zhang and shared under a CC-BY-4.0 license.

Use Cases

• Compare progression-free and overall survival outcomes based on treatment regimen.
• Analyze tumor response rates (ORR, DCR) between combination therapies.
• Identify independent prognostic factors for survival based on clinical markers like BCLC stage, PIVKA-II, and AFP.
• Assess the safety profile and incidence of treatment-related adverse events across groups.

Strengths

• Includes data from 278 patients, with 58 matched pairs for analysis.
• Reports specific clinical outcomes: median OS of 23.1 vs 12.0 months and median PFS of 13.0 vs 7.8 months.
• Identifies independent prognostic factors with hazard ratios and p-values from multivariable Cox regression.

Limitations

• Single-center retrospective design limits generalizability of findings.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying raw data is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Single-center retrospective study using propensity score matching.

Time Range

2021 to 2024

Freshness

Last updated 2026-04 16 05:16:30; freshness should be verified.

Geography

null